WS #16365
Holding: newest synthesis is 21d 5h old
Moderna shares are down 18% in premarket trading after leaked data from a melanoma trial showed a lack of benefit, triggering a significant sell-off. This event highlights the persistent binary risk in biotech clinical trials, particularly for companies heavily reliant on oncology pipelines.
Pharma and Clinical Data
Moderna shares are down 18% in premarket trading after leaked data from a melanoma trial showed a lack of benefit, triggering a significant sell-off. This event highlights the persistent binary risk in biotech clinical trials, particularly for companies heavily reliant on oncology pipelines.